|
|
CpG M362 |
|
Vaxjo ID |
266 |
|
Vaccine Adjuvant Name |
CpG M362 |
|
Alternative Names |
(Class C oligodeoxynucleotide) |
|
Adjuvant VO ID |
VO_0005753
|
|
Description |
CpG M362 is a Class C CpG oligodeoxynucleotide that acts as a TLR9 agonist, stimulating both B cells and plasmacytoid dendritic cells (pDCs). It serves as a potent immunoadjuvant to reverse immune tolerance and restore HBV-specific T-cell responses. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
Oligodeoxynucleotides (ODNs) containing class C unmethylated cytosine-guanine dinucleotide (CpG-C) motifs may provide potential adjuvants for the immunotherapeutic strategy against CHB, since CpG-C ODNs stimulate both B cell and dendritic cell (DC) activation. |
|
Structure |
Synthetic single-stranded DNA Contains unmethylated CpG motifs (Class C structure) |
|
Storage |
Stored at –80 °C in serum samples; CpG M362 assumed stable under standard ODN storage conditions (–20 to –80 °C dry) |
|
Preparation |
CpG M362 sourced from Invivogen Mixed with 2 μg rHBVvac per mouse 10 μg CpG M362 administered per dose (s.c.) once weekly for 3 weeks |
|
Dosage |
10 μg CpG M362 + 2 μg rHBVvac per mouse Subcutaneous injection on days 1, 8, and 15 |
|
Function |
Chronic Hepatitis B virus (CHB) infection is a global public health problem. Oligodeoxynucleotides (ODNs) containing class C unmethylated cytosine-guanine dinucleotide (CpG-C) motifs may provide potential adjuvants for the immunotherapeutic strategy against CHB, since CpG-C ODNs stimulate both B cell and dendritic cell (DC) activation. However, the efficacy of CpG-C ODN as an anti-HBV vaccine adjuvant remains unclear. In this study, we demonstrated that CpG M362 (CpG-C ODN) as an adjuvant in anti-HBV vaccine (cHBV-vaccine) successfully and safely eliminated the virus in HBV-carrier mice. The cHBV-vaccine enhanced DC maturation both in vivo and in vitro, overcame immune tolerance, and recovered exhausted T cells in HBV-carrier mice. Furthermore, the cHBV-vaccine elicited robust hepatic HBV-specific CD8+ and CD4+ T cell responses, with increased cellular proliferation and IFN-γ secretion. Additionally, the cHBV-vaccine invoked a long-lasting follicular CXCR5+ CD8+ T cell response following HBV re-challenge. Taken together, CpG M362 in combination with rHBVvac cleared persistent HBV and achieved long-term virological control, making it a promising candidate for treating CHB. |
|
Safety |
Safe in mice No liver toxicity (ALT levels unchanged) No adverse events reported |
| References |
Zhao et al., 2022: Zhao H, Han Q, Yang A, Wang Y, Wang G, Lin A, Wang X, Yin C, Zhang J. CpG-C ODN M362 as an immunoadjuvant for HBV therapeutic vaccine reverses the systemic tolerance against HBV. International journal of biological sciences. 2022; 18(1); 154-165. [PubMed: 34975324].
|
|
